Commerzbank Aktiengesellschaft FI increased its position in shares of Stryker Co. (NYSE:SYK – Free Report) by 141.4% during the third quarter, Holdings Channel reports. The fund owned 3,577 shares of the medical technology company’s stock after acquiring an additional 2,095 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Stryker were worth $1,292,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the company. Centennial Bank AR increased its stake in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after buying an additional 48 shares during the period. Central Pacific Bank Trust Division acquired a new position in Stryker in the 1st quarter valued at approximately $39,000. HBW Advisory Services LLC acquired a new position in Stryker in the 3rd quarter valued at approximately $42,000. Grove Bank & Trust increased its stake in Stryker by 84.8% in the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after buying an additional 56 shares during the period. Finally, Sachetta LLC increased its stake in Stryker by 16.3% in the 2nd quarter. Sachetta LLC now owns 242 shares of the medical technology company’s stock valued at $80,000 after buying an additional 34 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.
Insider Buying and Selling at Stryker
In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the completion of the sale, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,685,213.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the transaction, the chief financial officer now owns 2,852 shares of the company’s stock, valued at approximately $949,716. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 220,068 shares of company stock valued at $71,811,372 in the last ninety days. Company insiders own 5.90% of the company’s stock.
Wall Street Analyst Weigh In
Read Our Latest Analysis on SYK
Stryker Price Performance
NYSE SYK opened at $363.24 on Thursday. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. The company has a fifty day simple moving average of $357.99 and a 200 day simple moving average of $343.59. The company has a market cap of $138.42 billion, a P/E ratio of 40.49, a P/E/G ratio of 2.83 and a beta of 0.91. Stryker Co. has a 1 year low of $255.22 and a 1 year high of $374.63.
Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The business had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same period in the prior year, the firm earned $2.54 EPS. Stryker’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, sell-side analysts predict that Stryker Co. will post 12 EPS for the current year.
Stryker Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend is Monday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 35.67%.
About Stryker
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Featured Stories
- Five stocks we like better than Stryker
- Insider Trading – What You Need to Know
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Earnings Per Share Calculator: How to Calculate EPS
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Using the MarketBeat Stock Split Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.